346 related articles for article (PubMed ID: 9417570)
41. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
Jespersen J
Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
[TBL] [Abstract][Full Text] [Related]
42. Oral contraceptives and thromboembolism.
IPPF Med Bull; 1967; 1(5):4. PubMed ID: 12304982
[TBL] [Abstract][Full Text] [Related]
43. Incidence of venous thromboembolism in families with inherited thrombophilia.
Simioni P; Sanson BJ; Prandoni P; Tormene D; Friederich PW; Girolami B; Gavasso S; Huisman MV; Büller HR; Wouter ten Cate J; Girolami A; Prins MH
Thromb Haemost; 1999 Feb; 81(2):198-202. PubMed ID: 10063991
[TBL] [Abstract][Full Text] [Related]
44. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors.
Tanis BC; Rosendaal FR
Semin Vasc Med; 2003 Feb; 3(1):69-84. PubMed ID: 15199494
[TBL] [Abstract][Full Text] [Related]
45. Haemostatic changes and the oral contraceptive pill.
Norris LA; Bonnar J
Baillieres Clin Obstet Gynaecol; 1997 Sep; 11(3):545-64. PubMed ID: 9488791
[TBL] [Abstract][Full Text] [Related]
46. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
Winkler UH
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
[TBL] [Abstract][Full Text] [Related]
47. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
Meurer LN; Slawson JG
J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
[No Abstract] [Full Text] [Related]
48. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism.
Andersen BS; Olsen J; Nielsen GL; Steffensen FH; Sørensen HT; Baech J; Gregersen H
Thromb Haemost; 1998 Jan; 79(1):28-31. PubMed ID: 9459317
[TBL] [Abstract][Full Text] [Related]
49. [Metabolic risks of oral contraception].
Monier L
Rev Int Pediatr; 1988 Feb; (178):64-5. PubMed ID: 12282576
[TBL] [Abstract][Full Text] [Related]
50. [Effect of hormonal changes in women on hemostasis].
Malý J; Dulícek P
Vnitr Lek; 2002 Dec; 48(12):1169-73. PubMed ID: 12642936
[TBL] [Abstract][Full Text] [Related]
51. The APC-PCI concentration as an early marker of activation of blood coagulation: a study of women on combined oral contraceptives.
Bremme K; Hamad RR; Berg E; Strandberg K; Stenflo J
Thromb Res; 2012 Oct; 130(4):636-9. PubMed ID: 22154243
[TBL] [Abstract][Full Text] [Related]
52. German court lifts OC prescription ban.
Contracept Technol Update; 1998 Mar; 19(3):41-2. PubMed ID: 12293274
[TBL] [Abstract][Full Text] [Related]
53. [Ovulation inhibitors: the significance of estrogen dose].
Kuhl H
Geburtshilfe Frauenheilkd; 1990 Dec; 50(12):910-22. PubMed ID: 2086334
[TBL] [Abstract][Full Text] [Related]
54. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium.
Martinelli I; De Stefano V; Taioli E; Paciaroni K; Rossi E; Mannucci PM
Thromb Haemost; 2002 May; 87(5):791-5. PubMed ID: 12038778
[TBL] [Abstract][Full Text] [Related]
55. Oral contraception and thrombophilia.
Blickstein D; Blickstein I
Curr Opin Obstet Gynecol; 2007 Aug; 19(4):370-6. PubMed ID: 17625421
[TBL] [Abstract][Full Text] [Related]
56. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
[TBL] [Abstract][Full Text] [Related]
57. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives.
Alhenc-Gelas M; Plu-Bureau G; Guillonneau S; Kirzin JM; Aiach M; Ochat N; Scarabin PY
J Thromb Haemost; 2004 Sep; 2(9):1594-600. PubMed ID: 15333036
[TBL] [Abstract][Full Text] [Related]
58. Oral contraceptives and the risk of DVT.
Piegsa K; Guillebaud J
Practitioner; 1996 Sep; 240(1566):544-51. PubMed ID: 8984464
[TBL] [Abstract][Full Text] [Related]
59. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
Gaspard U; Dubois M
Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
[TBL] [Abstract][Full Text] [Related]
60. Oral contraceptives and venous thromboembolism: consensus conference statement.
Dialogues in Contraception Consensus Conference (1995: Chicago)
Dialogues Contracept; 1996; ():1-8. PubMed ID: 12320455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
